Partner Michael Abernathy spoke to Law360 about one of the biggest patent rulings of the year, Juno Therapeutics Inc. et al. v. Kite Pharma Inc. The ruling—which reversed a $1.1 billion judgment against Gilead’s Kite Pharma Inc. for infringing Bristol-Myers’ cancer immunotherapy patent for the drug Yescarta—concluded that the patent is invalid because it lacks adequate written description support. This could encourage more challenges to antibody patents, Mike observed. “As a litigator in this field, I now look at life and say, ‘Antibody claims will certainly be attacked more frequently in litigation.’”